Form 8-K - Current report:
SEC Accession No. 0001213900-24-096245
Filing Date
2024-11-12
Accepted
2024-11-12 08:05:34
Documents
16
Period of Report
2024-11-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0220614-8k_cerothera.htm   iXBRL 8-K 46915
2 COMMON STOCK PURCHASE AGREEMENT, BY AND BETWEEN CERO THERAPEUTICS HOLDINGS, INC. ea022061403ex10-1_cerothera.htm EX-10.1 455391
3 REGISTRATION RIGHTS AGREEMENT, BY AND BETWEEN CERO THERAPEUTICS HOLDINGS, INC., ea022061403ex10-2_cerothera.htm EX-10.2 145347
  Complete submission text file 0001213900-24-096245.txt   997031

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE cero-20241108.xsd EX-101.SCH 3798
5 XBRL DEFINITION FILE cero-20241108_def.xml EX-101.DEF 26673
6 XBRL LABEL FILE cero-20241108_lab.xml EX-101.LAB 36817
7 XBRL PRESENTATION FILE cero-20241108_pre.xml EX-101.PRE 25297
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0220614-8k_cerothera_htm.xml XML 5942
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

EIN.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40877 | Film No.: 241443553
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)